Loading...
Loading...
RUBY| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 42.9M |
| Operating I/L | -42.9M |
| Other Income/Expense | -1.3M |
| Interest Income | 0.3M |
| Pretax | -44.2M |
| Income Tax Expense | 1.3M |
| Net Income/Loss | -45.6M |
Rubius Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of red cell therapeutics (RCTs) for severe diseases. The company's product pipeline includes RTX-240 and RTX-224 for solid tumor cancer treatment, RTX-aAPC for cancer therapy, RTX-321 for HPV-positive tumor treatment, and RTX-T1D for type 1 diabetes management.
